Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab. METHODS: We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab. The primary end point was progression-free survival. RESULTS: A total of 599 patients received cetuximab plus FOLFIRI, and 599 received FOLFIRI alone. The hazard ratio for progression-free survival in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% confidence interval [CI], 0.72 to 0.99; P=0.048). There was no significant difference in the overall survival between the two treatment groups (hazard ratio, 0.93; 95% CI, 0.81 to 1.07; P=0.31). There was a significant interaction between treatment group and KRAS mutation status for tumor response (P=0.03) but not for progression-free survival (P=0.07) or overall survival (P=0.44). The hazard ratio for progression-free survival among patients with wild-type-KRAS tumors was 0.68 (95% CI, 0.50 to 0.94), in favor of the cetuximab-FOLFIRI group. The following grade 3 or 4 adverse events were more frequent with cetuximab plus FOLFIRI than with FOLFIRI alone: skin reactions (which were grade 3 only) (in 19.7% vs. 0.2% of patients, P<0.001), infusion-related reactions (in 2.5% vs. 0%, P<0.001), and diarrhea (in 15.7% vs. 10.5%, P=0.008). CONCLUSIONS: First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer. The benefit of cetuximab was limited to patients with KRAS wild-type tumors. (ClinicalTrials.gov number, NCT00154102.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sub-analysis revealed that the benefits of cetuximab were limited to patients with KRAS wild-type (wt) tumors.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“The results of this trial demonstrated a decrease in progression-free survival but no difference in overall survival.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“Some large clinical trials have shown that FOLFIRI (leucovorin + 5-FU + irinotecan) or FOLFOX regimens combined with EGFR inhibitors can benefit KRAS-WT CRC.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“However, CRC with KRAS mutations do not benefit from EGFR inhibitors, possibly because activation of KRAS does not depend upstream on EGFR [149,150,151,152].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“According to the CRYSTAL trial, the application of cetuximab and FOLFIRI in first-line treatment can reduce the risk of progression by 15% and increase overall survival (OS) by 8.2 months in patients who have KRAS WT mCRC compared with patients taking FOLFIRI alone [5].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [5]
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Statistical Methods for Rates and Proportions, 2nd ed
GROVE, W. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.12.1644-a · Cited by 3,748
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Research works printed but not linked: 3
- Rougier P, 2004, J Clin Oncol, 22, 248s, 10.1200/jco.2004.22.14_suppl.3513 · doi:10.1200/jco.2004.22.14_suppl.3513
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Schilsky RL, 2002, Clin Cancer Res, 8, 935
Cited by
Items 201–300 of 1,017
The Notch pathway in colorectal cancer
Vinson, K. E., George, D. C., Fender, A. W., Bertrand, F. E., & Sigounas, G. (2016) · International Journal of Cancer · doi:10.1002/ijc.29800 · Cited by 175
“Typically, the first-line drug regimens used in the treatment of CRC consist of fluorouracil together with leucovorin and irinotecan or oxaliplatin and can also be combined with bevacizumab.(60) Cetuximab, an IgG1 monoclonal antibody against the epidermal growth factor receptor, in combination with irinotecan, has bee…”
BackgroundSmart Nanocarriers as an Emerging Platform for Cancer Therapy: A Review
Kenchegowda, M., Rahamathulla, M., Hani, U., Begum, M. Y., Guruswamy, S., Osmani, R. A. M., Gowrav, M. P., Alshehri, S., Ghoneim, M. M., Alshlowi, A., et al. (2021) · Molecules · doi:10.3390/molecules27010146 · Cited by 167
“Rituximab is an antibody approved by FDA for non-lymphoma Hodgkin’s treatment [137].”
BackgroundNew concepts in the diagnosis and management of choroidal metastases
Mathis, T., Jardel, P., Loria, O., Delaunay, B., Nguyen, A.-M., Lanza, F., Mosci, C., Caujolle, J.-P., Kodjikian, L., & Thariat, J. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.09.003 · Cited by 172
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Kaiser, F., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01140-9 · Cited by 173
“With regard to toxicity, no new or unexpected toxicities were observed, and adverse events of grade 3 or higher were in accordance with previous reports.(9,10) Due to expected toxicities of cetuximab, such as anaphylactic reactions, the number of patients unevaluable according to the protocol was higher in the cetuxim…”
ResultEmerging strategies for treating metastasis
Esposito, M., Ganesan, S., & Kang, Y. (2021) · Nature Cancer · doi:10.1038/s43018-021-00181-0 · Cited by 172
Shao, Y., Lin, Z., Hsu, C., Shen, Y., Hsu, C., & Cheng, A. (2010) · Cancer · doi:10.1002/cncr.25257 · Cited by 173
“A recent example of K-ras mutation in patients with advanced colorectal cancer as a negative predictor for the efficacy of cetuximab, a monoclonal antibody that targets the epidermal growth factor receptor, demonstrated how a negative predictor may help to tailor better, personalized cancer therapy.(36) In terms of ou…”
BackgroundManagement of colorectal cancer presenting with synchronous liver metastases
Siriwardena, A. K., Mason, J. M., Mullamitha, S., Hancock, H. C., & Jegatheeswaran, S. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.90 · Cited by 176
Monoclonal antibodies for the treatment of cancer
Shuptrine, C. W., Surana, R., & Weiner, L. M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.009 · Cited by 170
Genetics of inflammatory bowel disease: beyond NOD2
Mirkov, M. U., Verstockt, B., & Cleynen, I. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30111-x · Cited by 171
The Developing Story of Predictive Biomarkers in Colorectal Cancer
Boussios, S., Ozturk, M., Moschetta, M., Karathanasi, A., Zakynthinakis-Kyriakou, N., Katsanos, K., Christodoulou, D., & Pavlidis, N. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010012 · Cited by 168
“In the CRYSTAL study [59], patients were randomized to receive cetuximab plus FOLFIRI, versus FOLFIRI alone.”
MethodBiomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development
Tan, D. S. W., Thomas, G. V., Garrett, M. D., Banerji, U., de Bono, J. S., Kaye, S. B., & Workman, P. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181bd0445 · Cited by 171
Tumor Heterogeneity in Colorectal Cancer: What Do We Know So Far?
Sagaert, X., Vanstapel, A., & Verbeek, S. (2018) · Pathobiology · doi:10.1159/000486721 · Cited by 172
Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147
Gonsalves, W. I., Mahoney, M. R., Sargent, D. J., Nelson, G. D., Alberts, S. R., Sinicrope, F. A., Goldberg, R. M., Limburg, P. J., Thibodeau, S. N., Grothey, A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju106 · Cited by 170
“The presence of a KRAS mutation is predictive for resistance to anti-EFGR monoclonal antibodies (mAbs) in advanced colon cancer (7,8).”
Dahabreh, I. J., Terasawa, T., Castaldi, P. J., & Trikalinos, T. A. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-1-201101040-00006 · Cited by 172
“Study, Year (Reference) Amado et al, 2008 (14) Cappuzzo et al, 2008 (58) Freeman et al, 2008 (61) Gonçalves et al, 2008 (62) Karapetis et al, 2008 (15) Garm Spindler et al, 2009 (67) Jacobs et al, 2009 (68) Laurent-Puig et al, 2009 (69) Sohn et al, 2009 (80) Van Cutsem et al, 2009 (16) Graziano et al, 2010 (83) Sartor…”
InfluentialA Review of the Most Promising Biomarkers in Colorectal Cancer: One Step Closer to Targeted Therapy
Deschoolmeester, V., Baay, M., Specenier, P., Lardon, F., & Vermorken, J. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0025 · Cited by 166
Licitra, L., Störkel, S., Kerr, K. M., Van Cutsem, E., Pirker, R., Hirsch, F. R., Vermorken, J. B., von Heydebreck, A., Esser, R., Celik, I., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.018 · Cited by 167
Silencing CDR1as inhibits colorectal cancer progression through regulating microRNA-7
Tang, W., Ji, M., He, G., Yang, L., Niu, Z., Jian, M., Wei, Y., Ren, L., & Xu, J. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s131597 · Cited by 167
Jones, R. P., Sutton, P. A., Evans, J. P., Clifford, R., McAvoy, A., Lewis, J., Rousseau, A., Mountford, R., McWhirter, D., & Malik, H. Z. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.37 · Cited by 166
“Mutations in KRAS have been clearly demonstrated to confer resistance to systemic anti-EGFR therapies in large prospective studies (Van Cutsem et al, 2009, 2011; Bokemeyer et al, 2009).”
BackgroundTargeted therapies for non-small cell lung cancer
Dempke, W. C. M., Suto, T., & Reck, M. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2009.10.012 · Cited by 164
“Cetuximab was initially introduced as treatment for metastatic colorectal cancer and is now well established in all lines of treatment [10].”
BackgroundFirst-line chemotherapy for mCRC—a review and evidence-based algorithm
Cremolini, C., Schirripa, M., Antoniotti, C., Moretto, R., Salvatore, L., Masi, G., Falcone, A., & Loupakis, F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.129 · Cited by 162
Peeters, M., Kafatos, G., Taylor, A., Gastanaga, V. M., Oliner, K. S., Hechmati, G., Terwey, J.-H., & van Krieken, J. H. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.017 · Cited by 163
Rizzo, S., Bronte, G., Fanale, D., Corsini, L. R., Silvestris, N., Santini, D., Gulotta, G., Bazan, V., Gebbia, N., Fulfaro, F., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70021-9 · Cited by 177
Okines, A., Puerto, O. D., Cunningham, D., Chau, I., Van Cutsem, E., Saltz, L., & Cassidy, J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605259 · Cited by 163
Lee, K.-W., Lee, S. S., Kim, S.-B., Sohn, B. H., Lee, H.-S., Jang, H.-J., Park, Y.-Y., Kopetz, S., Kim, S. S., Oh, S. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1374 · Cited by 163
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Acquired resistance to EGFR‐targeted therapies in colorectal cancer
Van Emburgh, B. O., Sartore-Bianchi, A., Di Nicolantonio, F., Siena, S., & Bardelli, A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.003 · Cited by 160
“Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.L., Van Laethem, J.L., Maurel, J., Richardson, G., Wolf, M., Amado, R.G., 2007.”
BackgroundInfluentialMetastatic Colon Cancer, Version 3.2013: Featured Updates to the NCCN Guidelines
Benson, A. B., Bekaii-Saab, T., Chan, E., Chen, Y.-J., Choti, M. A., Cooper, H. S., Engstrom, P. F., Enzinger, P. C., Fakih, M. G., Fenton, M. J., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0022 · Cited by 161
Afrăsânie, V.-A., Marinca, M. V., Alexa-Stratulat, T., Gafton, B., Păduraru, M., Adavidoaiei, A. M., Miron, L., & Rusu, C. (2019) · Radiology and Oncology · doi:10.2478/raon-2019-0033 · Cited by 159
Molinari, F., Felicioni, L., Buscarino, M., De Dosso, S., Buttitta, F., Malatesta, S., Movilia, A., Luoni, M., Boldorini, R., Alabiso, O., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3137 · Cited by 159
Review article: systemic treatment of hepatocellular carcinoma
Pinter, M., & Peck‐Radosavljevic, M. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14913 · Cited by 160
Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer
Marín, J. J. G., de Medina, F. S., Castaño, B., Bujanda, L., Romero, M. R., Martínez‐Augustin, O., del Moral-Ávila, R., & Briz, Ó. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.638303 · Cited by 169
da Cunha Santos, G., Dhani, N., Tu, D., Chin, K., Ludkovski, O., Kamel‐Reid, S., Squire, J., Parulekar, W., Moore, M. J., & Tsao, M. S. (2010) · Cancer · doi:10.1002/cncr.25393 · Cited by 158
“The small numbers of patients who had wild-type KRASmake comparisons difficult with data from randomized trials in colorectal carcinoma, in which a benefit from anti-EGFR monoclonal antibodies was limited to KRAS wild-type tumors.(10,11,21) Currently, the molecular basis of this interaction is unknown.”
Meng, X., Xia, W., Xie, P., Zhang, R., Li, W., Wang, M., Xiong, F., Liu, Y., Fan, X., Xie, Y., et al. (2019) · European Radiology · doi:10.1007/s00330-018-5763-x · Cited by 158
Bullock, A. J., Schlechter, B. L., Fakih, M., Tsimberidou, A. M., Grossman, J. E., Gordon, M. S., Wilky, B. A., Pimentel, A., Mahadevan, D., Balmanoukian, A. S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03083-7 · Cited by 181
Patient‐derived xenografts for individualized care in advanced sarcoma
Stebbing, J., Paz, K., Schwartz, G. K., Wexler, L. H., Maki, R., Pollock, R. E., Morris, R., Cohen, R., Shankar, A., Blackman, G., et al. (2014) · Cancer · doi:10.1002/cncr.28696 · Cited by 156
“For example, among the subpopulation of metastatic colorectal cancers that carry the wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS) allele, objective responses to antiepidermal growth factor receptor therapeutics is still confined to 13% to 17% of patients.(22-24) Although the identification of v-raf muri…”
BackgroundTreatment of colorectal cancer in the elderly
Millán, M., Merino, S., Caro, A., Feliu, F., Escuder, J., & Francesch, T. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i10.204 · Cited by 177
Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study
Zaanan, A., Costes, L., Gauthier, M., Malka, D., Locher, C., Mitry, E., Tougeron, D., Lecomte, T., Gornet, J., Sobhani, I., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq038 · Cited by 160
Taieb, J., Zaanan, A., Le Malicot, K., Julié, C., Blons, H., Mineur, L., Bennouna, J., Tabernero, J., Mini, E., Folprecht, G., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5225 · Cited by 154
Self-citationDillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 205
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.
Liao, H.-W., Hsu, J.-M., Xia, W., Wang, H.-L., Wang, Y.-N., Chang, W.-C., Arold, S. T., Chou, C.-K., Tsou, P.-H., Yamaguchi, H., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82826 · Cited by 155
Chen, J. S., Hsu, C., Chiang, N., Tsai, C. S., Tsou, H., Huang, S.-F., Bai, L., Chang, I. ‐., Shiah, H.-S., Ho, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv035 · Cited by 155
“Recent studies demonstrated KRAS mutations as a negative predictor for the therapeutic efficacy of anti-EGFR antibodies in mCRC patients [6].”
BackgroundSchmiegel, W., Scott, R. J., Dooley, S., Lewis, W., Meldrum, C. J., Pockney, P., Draganic, B., Smith, S., Hewitt, C., Philimore, H., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12023 · Cited by 152
“The identification of patients wild-type (WT) for KRAS codons 12 and 13 mutations increased response rates to anti-EGFR therapy by as much as 60% (Douillard et al., 2010; Van Cutsem et al., 2009a) and reinforced the approach of incorporating molecular diagnostics into clinical practice.”
BackgroundMethodDucreux, M. P., Malka, D., Mendiboure, J., Etienne, P.-L., Texereau, P., Auby, D., Rougier, P. R., Gasmi, M., Castaing, M., Abbas, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70199-1 · Cited by 170
Self-citationBrudvik, K. W., Mise, Y., Chung, M. H., Chun, Y. S., Kopetz, S., Passot, G., Conrad, C. H., Maru, D. M., Aloia, T. A., & Vauthey, J. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5187-2 · Cited by 158
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Pearson, R. K. (2010) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79406-1 · Cited by 150
Richman, L. P., Vonderheide, R. H., & Rech, A. J. (2019) · Cell Systems · doi:10.1016/j.cels.2019.08.009 · Cited by 152
Receptor tyrosine kinase inhibitors in cancer
Ebrahimi, N., Fardi, E., Ghaderi, H., Palizdar, S., Khorram, R., Vafadar, R., Ghanaatian, M., Rezaei‐Tazangi, F., Baziyar, P., Ahmadi, A., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04729-4 · Cited by 168
A phase II study of RO4929097 in metastatic colorectal cancer
Strosberg, J. R., Yeatman, T., Weber, J., Coppola, D., Schell, M. J., Han, G., Almhanna, K., Kim, R., Valone, T., Jump, H., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.056 · Cited by 146
Dercle, L., Lu, L., Schwartz, L. H., Qian, M., Tejpar, S., Eggleton, P., Zhao, B., & Piessevaux, H. (2020) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djaa017 · Cited by 147
“This treatment has been found to prolong median OS by 8 months in RAS wild type (10) and increase overall response rate, but also to increase the rate of adverse events (8).”
BackgroundSelf-citationKim, S. T., Lim, D. H., Jang, K.-T., Lim, T., Lee, J., Choi, Y.-L., Jang, H.-L., Yi, J. H., Baek, K. K., Park, S. H., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0269 · Cited by 145
“Mol Cancer Ther; 10(10) October 2011 Molecular Cancer Therapeutics1996 NSCLC, but the frequencyofEGFRmutation inpancreatic cancer is very low and it is unclear whether EGFR mutation is associated with sensitivity to EGFR tyrosine kinase inhibitors (8, 15).”
ResultInfluentialKRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy
Siddiqui, A. D., & Piperdi, B. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0811-z · Cited by 163
Morkel, M., Riemer, P., Bläker, H., & Sers, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4750 · Cited by 144
Cause, Epidemiology, and Histology of Polyps and Pathways to Colorectal Cancer
Sullivan, B. A., Noujaim, M. G., & Roper, J. (2022) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2021.12.001 · Cited by 175
Cézé, N., Thibault, G., Goujon, G., Viguier, J., Watier, H., Dorval, E. D., & Lecomte, T. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1610-3 · Cited by 153
“With the exception of KRAS mutations, which are highly specific negative predictors of the response to anti-EGFR monoclonal antibodies, other factors predicting treatment failure following conventional therapies in advanced colorectal cancer are not well established [8, 9 ]. Identifying patients most likely or very un…”
BackgroundMechanisms of resistance to HER family targeting antibodies
Kruser, T. J., & Wheeler, D. L. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.01.009 · Cited by 156
“In 2004, the FDA approved it for use in combination with irinotecan for the treatment of EGFRexpressing metastatic CRC in patients who are refractory to irinotecan-based chemotherapies.”
BackgroundInfluentialTumor heterogeneity in the clinic: is it a real problem?
Jankú, F. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834013517414 · Cited by 159
Kim, M.-J., Lee, H. S., Kim, J. H., Kim, Y. J., Kwon, J. H., Lee, J.-O., Bang, S.-M., Park, K. U., Kim, D.-W., Kang, S.-B., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-347 · Cited by 140
Pinto, C., Fabio, F. D., Barone, C. A., Siena, S., Falcone, A., Cascinu, S., Llimpe, F. L. R., Stella, G. M., Schinzari, G., Artale, S. A., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605319 · Cited by 142
“…in metastatic colorectal cancer added to standard chemotherapy produces an improvement in the response rate in randomised studies in both a first-line setting and in patients with refractory disease (Cunningham et al, 2004; Sobrero et al, 2008; Bokemeyer et al, 2009; Van Cutsem et al, 2009).”
BackgroundMolecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions
Voss, J. S., Holtegaard, L. M., Kerr, S. E., Fritcher, E. G. B., Roberts, L. R., Gores, G. J., Zhang, J., Highsmith, W. E., Halling, K. C., & Kipp, B. R. (2013) · Human Pathology · doi:10.1016/j.humpath.2012.11.006 · Cited by 143
Integrating biomarkers in clinical trials
Buyse, M. E., Michiels, S., Sargent, D. J., Grothey, A. F., Matheson, A., & de Gramont, A. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.120 · Cited by 155
Phelip, J., Tougeron, D., Léonard, D., Benhaïm, L., Desolneux, G., Dupré, A., Michel, P., Penna, C., Tournigand, C., Louvet, C., et al. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.05.035 · Cited by 161
Mucinous Cancer of the Ovary: Overview and Current Status
Babaier, A., & Ghatage, P. (2020) · Diagnostics · doi:10.3390/diagnostics10010052 · Cited by 157
“Cetuximab use results in enhanced response rate and duration of response in the first-line treatment of metastatic CRC in patients where there is EGFR expression and where the tumor is KRAS wild-type [90].”
BackgroundTarantino, I., Warschkow, R., Worni, M., Cerny, T., Ulrich, A. B., Schmied, B. M., & Güller, U. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000860 · Cited by 140
Lunenburg, C. A. T. C., Henricks, L. M., Guchelaar, H., Swen, J. J., Deenen, M. J., Schellens, J. H. M., & Gelderblom, H. A. J. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.008 · Cited by 139
Microbial markers in colorectal cancer detection and/or prognosis
Villéger, R., Lopès, A., Véziant, J., Gagnière, J., Barnich, N., Billard, E., Boucher, D., & Bonnet, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i22.2327 · Cited by 158
Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs
Choi, H. Y., & Chang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713618 · Cited by 157
Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients
Rocca, Y. S., Roberti, M. P., Arriaga, J. M., Amat, M., Bruno, L., Pampena, M. B., Huertas, E., Loria, F. S., Pairola, A., Bianchini, M., et al. (2013) · Innate Immunity · doi:10.1177/1753425912453187 · Cited by 137
“EGFR expression is not the only determinant of Cetuximab response, as recent findings reported that patients with K-RAS point mutations are resistant to the treatment.(33,34) In addition, only 40% of patients with wild-type K-RAS respond to Cetuximab therapy; this observation implies that, for the remaining 60% of pat…”
BackgroundAdvancements in combining targeted therapy and immunotherapy for colorectal cancer
Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S., & Kopetz, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.05.001 · Cited by 155
Molecular‐targeted agents combination therapy for cancer: Developments and potentials
Li, F., Zhao, C., & Wang, L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28261 · Cited by 156
Detection of KRAS and BRAF Mutations in Colorectal Carcinoma
Arcila, M. E., Lau, C., Nafa, K., & Ladanyi, M. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.005 · Cited by 148
Zhang, W., Winder, T., Ning, Y., Pohl, A. C., Yang, D., Kahn, M. R., Lurje, G., LaBonte, M. J., Wilson, P. M., Gordon, M. A., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq315 · Cited by 143
“Cetuximab, an immunoglobulin G1 monoclonal antibody to the epidermal growth factor receptor (EGFR), has demonstrated clinical efficacy as monotherapy and when combined with chemotherapy in the treatment of advanced disease [2–7].”
Dohan, A. J. J., Gallix, B., Guiu, B., Malicot, K. L., Reinhold, C., Soyer, P. A., Bennouna, J., Ghiringhelli, F., Barbier, E., Boige, V., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316407 · Cited by 143
Luo, X.-J., Zhao, Q., Liu, J. S., Zheng, J., Qiu, M., Ju, H., & Xu, R. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.017 · Cited by 145
“Currently, the only marker with sufficient evidence to justify its use in routine clinical applications is KRAS mutation and the selection for anti-epidermal growth factor receptor (EGFR) therapy.(122) Different sample types, small cohorts, algorithms with poor efficiency, as well as high heterogeneity of the individu…”
BackgroundThrombocytopenia in cancer patients
Liebman, H. A. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50011-4 · Cited by 143
Glasgow, M. D. K., & Chougule, M. B. (2015) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2015.2145 · Cited by 145
Two-stage hepatectomy for multiple bilobar colorectal liver metastases
Narita, M., Oussoultzoglou, É., Jaeck, D., Fuchschuber, P., Rosso, E., Pessaux, P., Marzano, E., & Bachellier, P. (2011) · British journal of surgery · doi:10.1002/bjs.7580 · Cited by 149
The current status of treatment for colorectal cancer in China: A systematic review
Zhang, Y., Chen, Z., & Li, J. (2017) · Medicine · doi:10.1097/md.0000000000008242 · Cited by 157
“5 vs 15 months) than chemotherapy alone.([40])”
An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review
Fornasier, G., Francescon, S., & Baldo, P. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0791-0 · Cited by 134
Cathomas, G. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00035 · Cited by 133
“The introduction of a targeted therapy using monoclonal anti-EGFR antibody, namely panitumumab and cetuximab, in combination chemotherapy or as a single agent, has added a further promising treatment option (4, 31).”
BackgroundMolecular phenotypes of colorectal cancer and potential clinical applications
Kocarnik, J. M., Shiovitz, S., & Phipps, A. I. (2015) · Gastroenterology Report · doi:10.1093/gastro/gov046 · Cited by 132
Morris, V., Overman, M. J., Jiang, Z.-Q., Garrett, C., Agarwal, S., Eng, C., Kee, B., Fogelman, D., Dasari, A., Wolff, R., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.06.001 · Cited by 132
“Additionally, greater understanding of the molecular pathways driving survival and proliferation of colorectal tumor cells has led to the approval of novel targeted therapies—namely, cetuximab and panitumumab—specifically tailored to inhibit epidermal growth factor receptor (EGFR) pathways and thereby thwart tumor gro…”
Santini, D., Tampellini, M., Vincenzi, B., Ibrahim, T., Ortega, C., Virzì, V., Silvestris, N., Berardi, R., Masini, C., Calipari, N., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr572 · Cited by 137
“With the newer treatment regimens, median survival of >20 months has been reported for patients with advanced CRC [5–10].”
Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130
“The CRYSTAL trial was a multicenter, phase 3 trial evaluating FOLFIRI plus cetuximab versus FOLFIRI alone for patients with unresectable colorectal cancer [16].”
MethodAn Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
Chu, E. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.05.005 · Cited by 134
Van Cutsem, E., Tejpar, S., Vanbeckevoort, D., Peeters, M., Humblet, Y., Gelderblom, H., Vermorken, J. B., Viret, F., Glimelius, B., Gallerani, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9243 · Cited by 132
“Skin reactions are common adverse effects of cetuximab and other EGFR-targeting agents and mainly develop within the first 3 weeks of treatment.(1-6) In the BOND study, a positive association between the development of cetuximabassociated skin reactions and clinical activity was demonstrated.”
BackgroundResultSelf-citationMolecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives
Geng, F., Wang, Z., Yin, H., Yu, J., & Cao, B. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2210 · Cited by 131
Current Targeted Therapy for Metastatic Colorectal Cancer
Ohishi, T., Kaneko, M. K., Yoshida, Y., Takashima, A., Kato, Y., & Kawada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021702 · Cited by 149
Review of biomarkers in colorectal cancer
Newton, K., Newman, W. G., & Hill, J. (2011) · Colorectal Disease · doi:10.1111/j.1463-1318.2010.02439.x · Cited by 140
Krabbamein í ristli og endaþarmi - yfirlitsgrein
Haraldsdóttir, S., Einarsdóttir, H. M., Smáradóttir, A., Gunnlaugsson, A., Halfdanarson, T. R., & Hálfdánarson, Þ. R. (2014) · Læknablaðið · doi:10.17992/lbl.2014.02.531 · Cited by 146
Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
Hsu, H.-C., Thiam, T. K., Lu, Y.-J., Yeh, C. Y., Tsai, W.-S., You, J. F., Hung, H. Y., Tsai, C.-N., Hsu, A., Chen, H.-C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8076 · Cited by 131
“In the first-line therapy group, patients with mCRC received cetuximab plus chemotherapy with FOLFIRI (irinotecan and infusional 5-fluorouracil with leucovorin) [8].”
BackgroundMethodAre KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Yokota, T. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012799014968 · Cited by 126
“Keywords: Anti-EGFR monoclonal antibody, BRAF, Cetuximab, Chemotherapy, Clinicopathological features, Colorectal cancer, Driver mutation, EGFR, KRAS codon 12, KRAS codon 13, KRAS p.G13D, Panitumumab, Predictive marker, Prognostic biomarker, Screening.”
Saridaki, Z., Tzardi, M., Papadaki, C., Sfakianaki, M., Pega, F., Kalikaki, A., Tsakalaki, E., Trypaki, M., Messaritakis, I., Stathopoulos, E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015980 · Cited by 126
Suto, T., Yokobori, T., Yajima, R., Morita, H., Fujii, T., Yamaguchi, S., Altan, B., Tsutsumi, S., Asao, T., & Kuwano, H. (2015) · Carcinogenesis · doi:10.1093/carcin/bgu242 · Cited by 125
The role of the PI3K pathway in colorectal cancer
Papadatos-Pastos, D., Rabbie, R., Ross, P., & Sarker, D. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.12.006 · Cited by 126
EGFR and KRAS in Colorectal Cancer
Markman, B., Ramos, F. J., Capdevila, J., & Tabernero, J. M. (2010) · Advances in clinical chemistry · doi:10.1016/s0065-2423(10)51004-7 · Cited by 147
Rahbari, N. N., Lordick, F., Fink, C., Bork, U., Stange, A., Jäger, D., Luntz, S. P., Englert, S., Rossion, I., Koch, M., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-142 · Cited by 134
Implementing prognostic and predictive biomarkers in CRC clinical trials
Schaeybroeck, S. V., Allen, W. L., Turkington, R. C., & Johnston, P. G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.15 · Cited by 141
Macedo, L. T., da Costa Lima, A. B., & Sasse, A. D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-89 · Cited by 126
Epidermal growth factor receptor as a biomarker for cervical cancer
Soonthornthum, T., Arias‐Pulido, H., Joste, N. E., Lomo, L. C., Muller, C. Y., Rutledge, T. L., & Verschraegen, C. F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq723 · Cited by 134
Péron, J., Maillet, D., Gan, H. K., Chen, E. X., & You, B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3981 · Cited by 125
Metadata
- Authors
- Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., Roh, J. K., Folprecht, G., Ruff, P., Stroh, C., Tejpar, S., Schlichting, M., Nippgen, J., & Rougier, P.
- Affiliations
- Klinikum Oldenburg (DE)
- Moscow City Oncology Hospital №62 (RU)
- Petz Aladár Megyei Oktató Kórház (HU)
- National University Hospital (SG)
- Yonsei University (KR)
- University Hospital Carl Gustav Carus (DE)
- University of the Witwatersrand (ZA)
- Merck KGaA, Darmstadt (Germany) (DE)
- Universitair Ziekenhuis Leuven (BE)
- Hôpital Ambroise-Paré (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-04-02
- Volume
- 360
- Issue
- 14
- Pages
- 1408-1417
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2095201384
- Cited by
- 3,877
- References
- 34
- Citations by year
- 2026: 83 · 2025: 87 · 2024: 105 · 2023: 136 · 2022: 169 · 2021: 173 · 2020: 194 · 2019: 199 · 2018: 172 · 2017: 221 · 2016: 275 · 2015: 307 · 2014: 337 · 2013: 328 · 2012: 331
- FWCI
- 179.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- cetuximab, FOLFIRI, metastatic colorectal cancer, first-line therapy, KRAS mutation status, epidermal growth factor receptor, progression-free survival, overall survival, treatment response, adverse events, irinotecan, 5-fluorouracil, leucovorin, skin reactions, diarrhea, infusion reactions, anti-EGFR therapy
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Genes, ras, Colorectal Neoplasms, Disease Progression, Kaplan-Meier Estimate, Young Adult, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.